We are currently in the process of updating the content for ECULIZUMAB. Our team is committed to providing you with accurate, up-to-date information to help you make well-informed decisions.
We understand that precise product details matter, and we’re working diligently to ensure the description meets our high standards. Please check back soon for the finalized content.
In the meantime, if you have any questions or need assistance, don’t hesitate to reach out to us via call or WhatsApp at +91 89391 69999. We’re here to help!

Eculizumab is a monoclonal antibody used to treat rare blood and kidney disorders. It was first approved by the US FDA in March 2007 for paroxysmal nocturnal hemoglobinuria (PNH) and later for other conditions such as atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG).

Eculizumab is approved for the following conditions:

• Paroxysmal Nocturnal Hemoglobinuria (PNH): Prevents destruction of red blood cells and reduces anaemia and risk of blood clots.

• Atypical Hemolytic Uremic Syndrome (aHUS): Helps protect kidneys and prevents organ damage caused by uncontrolled complement activation.

• Generalised Myasthenia Gravis (gMG): Reduces muscle weakness and improves daily functioning in patients with antibodies against acetylcholine receptors.

• Prevention of Complement-Mediated Organ Damage: Used in conditions where overactivation of the complement system can harm organs.

• Other Rare Complement-Mediated Disorders: May be prescribed for other conditions as determined by a physician.

Eculizumab is given intravenously (IV) by a healthcare professional in a hospital or clinic. Your doctor will determine the dose and frequency based on your condition. Infusions are typically administered every 2–4 weeks. You will be closely monitored for side effects during and after the infusion. Do not self-administer this medicine at home.

Like all medications, Eculizumab can cause side effects, although not everyone who takes it will experience them.

Serious

• Severe infections (due to immune system suppression)

• Infusion-related reactions (fever, chills, low blood pressure, difficulty breathing)

• Blood clots (deep vein thrombosis or pulmonary embolism)

• Liver problems (jaundice, dark urine, abdominal pain, nausea, vomiting)

• Allergic reactions (rash, swelling, severe itching, anaphylaxis)

Common

• Headache

• Fatigue

• Nausea

• Diarrhea

• Fever or mild chills

• Dizziness

• Cough or mild shortness of breath

• Skin rash or redness at the injection site

Eculizumab increases susceptibility to certain infections, especially meningococcal disease. Patients must be vaccinated against Neisseria meningitidis at least 2 weeks before starting treatment. Inform your physician if you have a history of infections or immune disorders.

• Do not take Eculizumab if you are allergic to it or any of its ingredients.

• Inform your doctor about liver or kidney problems before starting therapy.

• Let your healthcare provider know all medications, including prescription drugs, supplements, and herbal products. Certain medicines may interact with Eculizumab.

• Eculizumab is intended for adult patients or children under specialist supervision

• Follow your doctor’s instructions carefully regarding dose and schedule.

• Report any side effects or unusual health changes immediately.

• Inform your doctor if you have liver, lung, or kidney problems.

• Women who could become pregnant should use effective birth control during and after treatment.

• Maintain a healthy diet and stay well-hydrated.

• Use sun protection when outdoors, as skin may be sensitive during treatment.

1. https://www.drugs.com/monograph/Eculizumab.html

2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125166s358lbl.pdf

3. https://pubchem.ncbi.nlm.nih.gov/compound/Eculizumab

4. https://en.wikipedia.org/wiki/Eculizumab

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.